Clinical Report: Pathophysiological Mechanisms of Myocarditis Induced by ICIs
Overview
This report reviews the pathophysiological mechanisms of immune checkpoint inhibitor-induced myocarditis (ICI-MC), highlighting T-cell dysregulation and multicellular interactions. It emphasizes the importance of identifying biomarkers and targeted therapies to mitigate cardiotoxicity associated with ICIs.
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can lead to severe immune-related adverse events, including myocarditis. ICI-MC is rare yet potentially fatal, with mortality rates nearing 50%. Understanding the underlying mechanisms is crucial for improving diagnosis and management of this life-threatening condition.
Data Highlights
No numerical data available in the source material.
Key Findings
['ICI-MC is characterized by clonal expansion of cytotoxic CD8+ T cells and loss of regulatory T cells.', 'Macrophage polarization towards M1 phenotypes contributes to myocardial inflammation.', 'A five-phase multicellular framework describes the evolution of ICI-MC.', 'Candidate biomarkers and targeted therapies are essential for precision strategies in managing ICI-MC.', 'Early recognition and treatment of ICI-MC can significantly impact patient outcomes.']
Clinical Implications
Clinicians should be vigilant for signs of myocarditis in patients receiving ICIs, as early diagnosis and intervention are critical. Implementing a multimodal diagnostic approach and considering high-dose corticosteroids for treatment can improve management outcomes.
Conclusion
The insights into the pathophysiology of ICI-MC underscore the need for ongoing research into biomarkers and therapeutic strategies to enhance patient safety without compromising cancer treatment efficacy.
